An investment from Aflac Ventures and Artiman Ventures is financing the agreement, according to a March 23 press release. CellMax has also received series C financing for the test.
CellMax’s multimodal liquid biopsy test, FirstSight, is a noninvasive screening method for detection of colorectal cancer and precancerous polyps.
Sebela is a pharmaceutical company and a key player in the gastroenterology market. CellMax Life is a diagnostics company focused on cancer screening.
More articles on ASCs:
Michigan orhopedic group reports breach that exposed 28,658 patients’ information
7 developments in outpatient spine surgery in 2021
4 key questions on the future of spine surgery at ASCs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.